Cabozantinib

Cabozantinib. It is a small molecule inhibitor of multiple receptor tyrosine kinases, including MET, VEGFR2, and AXL. Developed by Exelixis, it is marketed under the brand names Cometriq and Cabometyx for the treatment of certain advanced cancers. Its mechanism disrupts key signaling pathways involved in tumor growth, angiogenesis, and metastasis.

Medical uses

Cabozantinib is approved by the U.S. Food and Drug Administration for the treatment of progressive, metastatic medullary thyroid cancer. It is also indicated for advanced renal cell carcinoma following prior anti-angiogenic therapy and for previously treated hepatocellular carcinoma in patients who have been previously treated with sorafenib. Clinical trials, such as the METEOR trial and the CELESTIAL trial, demonstrated significant improvements in progression-free survival and overall survival in these patient populations. The drug is used in second-line settings for renal cell carcinoma and continues to be studied in other malignancies like prostate cancer and non-small cell lung cancer through collaborations with organizations like the National Cancer Institute.

Adverse effects

Common adverse reactions include diarrhea, stomatitis, palmar-plantar erythrodysesthesia, hypertension, and fatigue. Serious adverse events can involve gastrointestinal perforation and fistula formation, major hemorrhage, and arterial thromboembolism events such as myocardial infarction or cerebrovascular accident. Management often requires dose interruptions or reductions, and patients require monitoring of blood pressure, liver function tests, and thyroid function due to risks of hypothyroidism. The European Medicines Agency and Health Canada include similar warnings in their product monographs regarding these risks.

Pharmacology

Cabozantinib functions as a potent inhibitor of multiple receptor tyrosine kinases. It primarily targets MET, VEGFR2, and AXL, which are implicated in oncogenesis, tumor angiogenesis, and the development of therapeutic resistance. The drug is administered orally and undergoes extensive metabolism in the liver, primarily via the cytochrome P450 enzyme CYP3A4. Its pharmacokinetics can be affected by co-administration with strong CYP3A4 inducers or inhibitors, such as rifampin or ketoconazole. The terminal half-life is approximately 55 hours, supporting once-daily dosing.

History

Cabozantinib was discovered and developed by the biopharmaceutical company Exelixis, headquartered in South San Francisco. Initial research focused on its potential to inhibit the MET pathway. The drug received its first FDA approval for medullary thyroid cancer in November 2012 under the brand name Cometriq. Subsequent approvals expanded its use; in April 2016, it was approved for renal cell carcinoma under the name Cabometyx, following positive results from the phase III METEOR trial. A key regulatory milestone occurred in January 2019 when the FDA approved it for hepatocellular carcinoma based on the CELESTIAL trial. Development has involved global clinical trials and regulatory reviews by the European Commission and Pharmaceuticals and Medical Devices Agency.

Society and culture

The drug is marketed under two brand names, Cometriq and Cabometyx, with the latter formulation used for renal cell carcinoma and hepatocellular carcinoma. Its high cost has been a subject of discussion within healthcare systems, involving analyses by organizations like the Institute for Clinical and Economic Review. Patient access programs have been established by Exelixis in various regions. The development of cabozantinib has been recognized with awards, and its clinical impact has been featured at major oncology conferences such as those held by the American Society of Clinical Oncology and the European Society for Medical Oncology. Ongoing research explores its combination with immunotherapy agents like nivolumab and ipilimumab.

Category:Antineoplastic drugs Category:Tyrosine kinase inhibitors